Cytokines performance during nivolumab treatment: A subgroup analysis of NIVACTOR study.

e18008Background: Nivolumab is approved for 2nd line R/M SCCHN, but only 20% of patients will benefit. Therefore, there is an unmet need for predictive markers. Nivactor is a prospective real-life...